معرفی
Aymeric Ravel-Chapuis serves as an Assistant Professor in the School of Pharmaceutical Sciences at the University of Ottawa since December 2022, with a cross-appointment in Cellular and Molecular Medicine within the Faculty of Medicine. His research is conducted at 451 Smyth Road, Ottawa, and he coordinates graduate courses including PHM 1516, CMM 8340, and CTM 8123, demonstrating active engagement in both research and academic instruction.
Dr. Ravel-Chapuis's research program centers on neuromuscular disease mechanisms, with particular emphasis on RNA-binding proteins (Staufen1, HuR) and their role in gene regulation within skeletal muscle. His work investigates cell signaling pathways like AMPK and HDAC6 in conditions including myotonic dystrophy type 1 (DM1) and muscular dystrophies, exploring how spliceopathy and protein dysregulation drive pathology. This molecular focus bridges basic science with therapeutic development for muscular disorders.
Analysis of his 2018-2024 publications reveals a concentrated research trajectory targeting DM1 pathology through RNA-processing interventions. Key trends include combinatorial therapies (exercise + pharmacological agents), sex-specific treatment responses, and HDAC6/AMPK modulation to correct splicing defects. His work consistently employs mouse models and muscle cell lines to evaluate therapeutic efficacy, with growing emphasis on translational applications for neuromuscular disorders.
Research operations are conducted at the University of Ottawa's neuroscience facility at 451 Smyth Road, which provides infrastructure for molecular, cellular, and physiological studies of skeletal muscle. This location supports his investigation of disease mechanisms and therapeutic development within the university's broader neuromuscular research ecosystem.
